120
Participants
Start Date
July 11, 2014
Primary Completion Date
May 18, 2016
Study Completion Date
November 30, 2016
Recombinant human antithrombin (ATryn)
Atryn 250 mg loading dose over 15 minutes, immediately followed by continuous infusion of 2000 mg per 24 hours. Total daily dose is 2250 mg for the first day and 2000 mg on subsequent days
Normal Saline 0.9%
Placebo Comparator: Normal Saline 0.9%
Columbia University Medical Center, New York
Duke University, Durham
University of Mississippi Medical Center, Jackson
University of South Florida, Tampa
University of Alabama, Birmingham
University of South Alabama, Mobile
Norton Healthcare, Louisville
Tri-State Maternal Fetal Health, Cincinnati
Saint John Hospital and Medical Center, Detroit
Northwestern University, Chicago
Barnes-Jewish Hospital, St Louis
Saint Louis University School of Medicine, St Louis
Oschner Baptist, New Orleans
University of Arkansas, Little Rock
University of Oklahoma Health Sciences Center, Oklahoma City
University of Texas Houston School of Medicine, Houston
University Texas Medical Branch, Galveston
Intermountain Health, Murray
University of Utah Hospitals & Clinics, Salt Lake City
University of California at Irvine, Orange
Erlanger Medical Center, Chattanooga
Yale New Haven Hospital, New Haven
Women & Infants Hospital, Providence
Lead Sponsor
rEVO Biologics
INDUSTRY